Design Therapeutics: Driehaus reports 5.83% stake
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Driehaus Capital Management LLC reported beneficial ownership of 3,650,681 Design Therapeutics, Inc. (DSGN) common shares, equal to 5.83% of the class, as of September 30, 2026. It reported shared voting and dispositive power over all 3,650,681 shares, with no sole voting or dispositive power. The shares are held by numerous clients in discretionary accounts managed by Driehaus; to its knowledge, no referenced client had rights to dividends or sale proceeds relating to more than 5% of the class.
Key Figures
Key Terms
beneficial ownership regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.